This meta-analysis categorized patients with HF based on the presence or absence of diabetes and showed that SGLT2 inhibitors significantly lowered the risk of hospitalizations for heart failure (HHF) among patients with and without diabetes; however, there was no statistically significant difference in cardiovascular mortality or serious adverse events. This evidence concerns the gene SLC5A2 and heart failure.